stars 1 stars 2 stars 3

SIMABS NV has developed a unique platform for fast, flexible and cost effective development and manufacturing of monoclonal antibodies. We deliver total solutions for your development and manufacturing by means of a new and unique manufacturing platform based on continuous bioprocessing. This platform allows us to produce several complex antibodies (monoclonal, bispecific, multivalent,…) in a range from milligrams to kilograms for biopharmaceutical companies. This platform will enable personalised medicine to become an affordable reality. We are a one stop shop with a lean and customer oriented project management approach. SIMABS offers additional services like: • Cell line development • USP/DSP development • Analytical and formulation development • Quality Management • Validation • Project Management • Technology Transfer to GMP • Regulatory Affairs • Clinical Research Contact us to learn more about our pharmaceutical contract development and manufacturing capabilities.

simAbs Questions

Koen Dierckx is the Co-founder and CEO of simAbs.

17 people are employed at simAbs.

Top simAbs Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users